Epithelial–mesenchymal transition (EMT) is an important biological process in tumor invasion and metastasis, and thus may be a potential indicator of the progression and drug resistance of breast cancer.

This study established a prognostic risk model for triple-negative breast cancer (TNBC) based on 13 EMT-related signature genes (EMGs).

High-risk patients with TNBC had shorter overall survival compared to low-risk patients and were more likely to experience immunosuppression and thus less likely to benefit from immune checkpoint inhibitor (ICI) therapy or chemotherapy, which aids the development of individualized therapy for patients with TNBC.